Calculus has launched its latest venture capital trust (VCT) offer in a bid to raise up to £10mn.
The tax efficient investment firm announced it will also have an over-allotment facility for an extra £10mn.
The VCT fund for 2023/24 is set to close in August 2024 and will offer investment in the technology, healthcare, and entertainment sectors.
Calculus said this fits with the government’s Enterprise Investment Scheme (EIS) objectives and is further attempt to ‘bolster the UK's innovative and high-growth potential companies'.
John Glencross, chief executive and co-founder of Calculus, said: "Our journey since launching the first HMRC approved EIS fund in 1999, has been one of growth.
“With this VCT offer, we are further solidifying our pledge to back the UK's most promising businesses. We believe that through this VCT, investors can not only benefit from capital growth and tax-free dividends, but also play a pivotal role in shaping the future of the UK's innovation landscape."
Investors in the VCT would see up to 30 per cent income tax relief, exemption from capital gains tax, and the potential for tax-free dividends.
Companies in the portfolio include Oxford BioTherapeutics, Optalitix, and Rotageek.
tara.o'connor@ft.com
What's your view?
Have your say in the comments section below or email us: ftadviser.newsdesk@ft.com
